Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: A single centre experience

International Journal of Clinical Practice

Volumn 68, Issue 1, 2014, Pages 20-27

  Bal, A M ^a   Shankland, G S ^b   Scott, G ^a   Imtiaz, T ^a   Macaulay, R ^a   McGill, M ^a  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CLINICAL ARTICLE; COST CONTROL; DRUG COST; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITAL POLICY; HUMAN; INTRAVENOUS TO ORAL SWITCH POLICY; MALE; MEDICATION THERAPY MANAGEMENT; MORTALITY; PRIORITY JOURNAL; RELAPSE; STEP DOWN THERAPY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; DRUG ADMINISTRATION; ECONOMICS; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION; POLICY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; ORGANIZATIONAL POLICY; RECURRENCE; TREATMENT OUTCOME; VORICONAZOLE;

EID: 84890459005     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12231     Document Type: Article

References (24)

1. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 (Suppl. 7): 19-37.
3. Ananda-Rajah MR, Slavin MA, Thursky KT,. The case for antifungal stewardship. Curr Opin Infect Dis 2012; 25: 107-15.
4. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011; 38: 16-26.
5. Chalmers C, Gaur S, Chew J, et al. Epidemiology and management of candidaemia-a retrospective, multicentre study in five hospitals in the UK. Mycoses 2011; 54: e795-800.
6. Denning DW, Kibbler CC, Barnes RA,. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
7. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
8. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
9. Ruhnke M, Rickerts V, Cornely OA, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54: 279-310.
10. http://www.whocc.no/ (accessed 20 January 2013).
11. British National Formulary 2011; 61: 374-5.
12. http://www.statistics.gov.uk/hub/population/ageing/older-people (accessed 27 October 2012).
13. Chalmers CM, Bal AM,. Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth 2011; 106: 827-31.
14. Aliyu SH, Enoch DA, Abubakar II, et al. Candidaemia in a large teaching hospital: a clinical audit. QJM 2006; 99: 655-63.
15. Das I, Nightingale P, Patel M, Jumaa P,. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 2011; 15: e759-63.
16. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
17. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB,. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect 2006; 12: 170-7.
18. Imtiaz T, Lee KK, Munro CA, et al. Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin. J Med Microbiol 2012; 61: 1330-4.
19. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M,. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-9.
20. Schelenz S, Barnes RA, Kibbler CC, Jones BL, Denning DW,. Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 2009; 58: 145-53.
21. Shah DN, Yau R, Weston J, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-51.
22. Lopez-Medrano F, San Juan R, Lizasoain M, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19: 56-61.
23. Hope WW, Billaud EM, Lestner J, Denning DW,. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580-6.
24. Eschenauer GA, Carver PL, Lin SW, et al. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J Antimicrob Chemother 2013; 68: 922-6.